![]() |
市場調查報告書
商品編碼
1463830
歐洲非侵入性通氣面罩市場規模和預測、區域佔有率、趨勢和成長機會分析報告範圍:按介面、應用、用途、尺寸、材料、產品類型、最終用戶和國家/地區Europe Noninvasive Ventilation Masks Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Interfaces, Application, Usage, Size, Material, Product Type, End User, and Country |
歐洲非侵入性通氣口罩市場預計將從2022年的7.1983億美元成長到2030年的10.7668億美元;預計2022年至2030年複合年成長率為5.2%。
非侵入性通氣 (NIV) 是透過面罩輸送氧氣(通氣支持),無需氣管內氣道。 NIV 透過減少呼吸功和改善氣體交換,提供與傳統機械通氣相當的生理益處。此介入措施被認為是治療慢性阻塞性肺病、心源性肺水腫和其他呼吸系統疾病的有效治療方法,且無併發症,如上呼吸道創傷、呼吸器相關性肺炎、呼吸肌無力和鼻竇炎。因此,呼吸系統疾病的日益普及可能會嚴重影響未來幾年歐洲非侵入性通氣口罩市場的預測。
慢性阻塞性肺病盛行率上升推動歐洲無創通氣面罩市場成長
慢性阻塞性肺病(COPD)是最重要的公共衛生議題之一。根據美國國家醫學圖書館2022年發表的《德國慢性阻塞性肺病患者家庭遠距監測計畫的有效性》一文,德國報告約600萬例慢性阻塞性肺病病例。一篇題為「體弱的瑞士人對慢性阻塞性肺病了解多少?」的文章指出。 2021 年發布的報告顯示,瑞士約有 40 萬人受到慢性阻塞性肺病 (COPD) 的影響。
患有潛在慢性阻塞性肺病且病情惡化、高碳酸血症性呼吸困難或呼吸衰竭的患者最有可能透過非侵入性通氣 (NIV) 成功治療。 NIV有效緩解呼吸肌肉壓力,增加潮氣量,降低呼吸頻率,減少橫膈呼吸做功,進而改善供氧,減少高碳酸血症,改善呼吸困難。 COPD 是 NIV 的理想選擇,因為治療可快速逆轉,並且可以提供額外的支持。
NIV 可降低 COPD 患者的氣管插管率、住院時間、機械通氣併發症和死亡率。最近的臨床實踐指南推薦 NIV 作為治療 COPD 急性呼吸衰竭 (ARF) 的第一線通氣支持。 NIV 面罩擴大用於治療慢性阻塞性肺病和呼吸衰竭患者。
NIV 有助於減少 COPD 惡化並伴隨呼吸衰竭的患者的插管和死亡率。面罩的類型可能會影響成功率。對於病情嚴重且患有 ARF 的患者,建議使用全面罩而不是鼻罩。因此,歐洲慢性阻塞性肺病和其他呼吸系統疾病盛行率的增加預計將推動市場的成長。
口腔、口鼻、混合、鼻、鼻枕、頭盔、頭套和其他面罩類型可導致患者不適、漏氣、幽閉恐懼症、皮膚發紅、眼睛刺激、皮膚破損和兒童臉部畸形。面罩底部的小洩漏不會影響 NIV 的性能。然而,大量洩漏或面罩眼部洩漏可能會引起關注。鼻樑疼痛表示面罩太緊或頂部不合適。必須重新調整或更換面罩,因為疼痛會加劇。
由於這種干預措施的日益普及,與 NIV 面罩相關的壓瘡是一個重要的臨床問題。壓瘡的發生與不良的臨床結果、增加的併發症和延長的住院時間有關,所有這些都會加劇急性疾病的後果。
確保面罩正確貼合至關重要。否則,氧氣可能會洩漏到眼睛中,引起刺激和結膜炎。使用全面罩可以干擾咳嗽並有效消除分泌物。此外,產生的過大壓力會影響患者產生足夠呼氣流速的能力,進而對分泌物的動員和咳嗽阻力產生不利影響,進而導致分泌物滯留。
因此,與 NIV 面罩相關的副作用阻礙了歐洲非侵入性通氣面罩市場的成長。
歐洲非侵入性通氣面罩市場分析是透過考慮以下部分進行的:介面、應用、用途、材料、尺寸、產品類型和最終用戶。從介面來看,市場分為口罩和配件。面罩部分包括鼻罩、面罩、鼻枕面罩、口腔面罩和全面罩/頭盔。面罩進一步細分為二氧化碳排放面罩和非排放面罩。 NIV 面罩的配件包括彎頭和替換彎頭、軟管、管子、皮膚屏障、鼻下/鼻墊以及頭帶/替換裝備。根據應用,歐洲非侵入性通氣面罩市場分為呼吸功能障礙、慢性阻塞性肺病、肺炎等。根據用途,市場進一步細分為兒科和成人。歐洲無創通氣口罩市場進一步按規模細分為大、中、小型。依材質又可分為矽膠、凝膠等。根據產品類型,市場分為一次性和可重複使用。根據最終用戶,市場分為醫院、重症和急診護理機構、門診手術中心等。歐洲非侵入性通氣口罩市場報告的範圍包括評估英國、德國、法國、奧地利、瑞士和歐洲其他地區的市場表現。
歐盟(EU)和世界衛生組織(WHO)是準備歐洲非侵入性通氣口罩市場報告時提到的主要主要和次要來源。
The Europe noninvasive ventilation masks market is expected to grow from US$ 719.83 million in 2022 to US$ 1,076.68 million by 2030; it is anticipated to record a CAGR of 5.2% from 2022 to 2030.
Non-invasive ventilation (NIV) is the delivery of oxygen (ventilation support) through a face mask, eliminating the need for an endotracheal airway. NIV provides comparable physiological benefits to conventional mechanical ventilation by reducing breathing work and improving gas exchange. The intervention is recognized as an effective treatment for respiratory failure in chronic obstructive pulmonary disease, cardiogenic pulmonary edema, and other respiratory conditions without complications, such as upper airway trauma, ventilator-associated pneumonia, respiratory muscle weakness, and sinusitis. Thus, the increasing prevalence of respiratory diseases will likely significantly impact the Europe noninvasive ventilation masks market forecast in the next few years.
Rising Prevalence of COPD Propels Europe Noninvasive Ventilation Masks Market Growth
Chronic obstructive pulmonary disease (COPD) is one of the most significant public health concerns. According to the article "Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany" published by the National Library of Medicine in 2022, Germany reported ~ 6 million COPD cases. According to an article titled "What knows a frail Swiss population about chronic obstructive pulmonary disease?" published in 2021, about 400,000 people were affected by COPD in Switzerland.
Patients with underlying COPDs who suffer from exacerbation of their diseases and hypercapnic dyspnoea or respiratory failure are most likely to be successfully treated with noninvasive ventilation (NIV). NIV effectively relieves the pressure on the respiratory muscles, increases tidal volume, decreases respiratory rate, and reduces the work of diaphragmatic breathing, resulting in an improvement in oxygen supply, a decrease in hypercapnia, and an improvement in dyspnea. A COPD is ideal for NIV as the treatment is quickly reversible, and additional support can be provided.
NIV reduces the endotracheal intubation rate, length of hospital stays, complications of mechanical ventilation, and mortality for COPD patients. Recent clinical practice guidelines recommend NIV as first-line ventilatory support for treating acute respiratory failure (ARF) in COPDs. NIV masks are increasingly used to treat people suffering from COPD and respiratory failure.
NIV helps reduce intubation and mortality in patients affected by COPD exacerbation with respiratory failure. The type of mask may impact the success rate. A full-face mask is recommended over nasal masks for patients who are seriously ill and suffer from ARF. Thus, Europe's increasing prevalence of COPD and other respiratory disorders is expected to fuel the market's growth.
Oral, oronasal, hybrid, nasal, nasal pillow, helmet, headgear, and other mask types can lead to patient discomfort, air leaks, claustrophobia, skin redness, eye irritation, skin breakdown, and facial deformity in children. A small leak at the bottom of the mask does not affect NIV's performance. However, a large leak or a leak in the eye of mask can be a concern. Pain on the nose bridge indicates that the mask is too tight or is poorly fitting at the top. The mask must be readjusted or replaced, as the pain can worsen.
Pressure ulcers associated with NIV masks are a significant clinical problem due to the increasing popularity of the intervention. The development of pressure ulcers is associated with poor clinical outcomes, increased complications, and extended hospital stays, all of which aggravate the consequences of acute illness.
It is essential to make sure that the mask fits properly. Otherwise, oxygen may leak into the eyes, causing irritation and conjunctivitis. Using a full-face mask can interfere with coughing and effectively eliminate secretions. In addition, the excess pressure generated can affect the patient's ability to generate sufficient expiratory flow rates, adversely impacting the mobilization of secretions and cough resistance that leads to the retention of secretions.
Thus, side effects associated with NIV masks hamper the growth of the Europe non-invasive ventilation masks market.
The Europe noninvasive ventilation masks market analysis has been carried out by considering the following segments: interfaces, application, usage, material, size, product type, and end user. By interfaces, the market is bifurcated into masks and accessories. The masks segment consists of a nasal mask, face mask, nasal pillow mask, oral mask, and total face mask/helmets. Face mask is further sub-segmented into CO2 venting face mask and non-vented face mask. Accessories of NIV masks include elbows and replacement elbows, hoses, tubes, skin barriers, under/over the nose cushions, and head strap/replacement gears. Based on application, the Europe non-invasive ventilation masks market is segmented into respiratory dysfunction, chronic obstructive pulmonary disease, pneumonia, and others. Based on the usage, the market is further segmented into pediatrics and adults. The Europe non-invasive ventilation masks market, by size, is further segmented into large, medium, and small. Based on material, it is further segmented into silicon, gel, and others. Based on product type, the market is bifurcated into single-use and reusable. Based on end user, the market is segmented into hospitals, critical and acute care settings, ambulatory surgical centers, and others. The scope of Europe noninvasive ventilation masks market report includes assessing the market performance in the UK, Germany, France, Austria, Switzerland, and the Rest of Europe.
European Union (EU) and World Health Organization (WHO) are key primary and secondary sources referred to while preparing the report on the Europe noninvasive ventilation masks market.
Note - Similar information would be provided for below list of companies